Neurocrine Biosciences (NBIX) Total Debt (2018 - 2024)

Neurocrine Biosciences (NBIX) posted quarterly Total Debt of $122.8 million for Q1 2024, down 27.81% on a QoQ basis from $170.1 million in Q4 2023.

Neurocrine Biosciences (NBIX) Total Debt (2018 - 2024) Analysis & Trends

Neurocrine Biosciences has reported Total Debt for 6 years, with the latest figure at $122.8 million in Q1 2024.

Total Debt for Q1 2024 came in at $122.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2024 was $122.8 million (changed N/A YoY), and the FY2023 annual result was $170.1 million, changed 0.41% from the prior year.
Total Debt eased to $122.8 million in Q1 2024, from $170.1 million in the prior quarter.
Over five years, Total Debt peaked at $425.0 million in Q3 2020 and troughed at $122.8 million in Q1 2024.
A 4-year average of $227.0 million and a median of $169.8 million in 2023 frame the typical range for Total Debt.
The largest YoY upside for Total Debt was 0.41% in 2023 against a maximum downside of 0.41% in 2023.
A 4-year view of Total Debt shows it stood at $425.0 million in 2020, then tumbled by 60.14% to $169.4 million in 2022, then rose by 0.41% to $170.1 million in 2023, then declined by 27.81% to $122.8 million in 2024.
Per Business Quant data, the three most recent Total Debt figures were $122.8 million in Q1 2024, $170.1 million in Q4 2023, and $169.9 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-	-5.81 Bn
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn	16.59 Bn
3	Zoetis	31.79 Bn	30.11 Bn	1.05 Bn	9.05 Bn
4	Takeda Pharmaceutical	28.69 Bn	22.89 Bn	5.10 Bn	31.47 Bn
5	United Therapeutics	22.25 Bn	19.58 Bn	683.80 Mn	-
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn	13.35 Bn
7	Neurocrine Biosciences	15.58 Bn	15.19 Bn	935.80 Mn	-
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn	3.92 Bn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	760.00 Mn
10	Alkermes	8.15 Bn	7.49 Bn	397.90 Mn	1.50 Bn

Download Data